(EMAILWIRE.COM, November 30, 2018 ) The global cardiac ablation market is poised to grow at a CAGR of 12.5% during 2014-2019, and is expected to reach a value of ~$883.1 Million in 2019. A number of factors such as growing geriatric population coupled with increasing population base of cardiovascular disease patients, technological advancements in the field of ablation devices, and growing awareness about benefits of cardiac ablation procedures over conventional therapeutic and surgical procedures are fuelling the growth of the global cardiac ablation market. However, high cost-containment measures taken by various governments and ongoing healthcare reforms in the U.S. are some of the key factors hampering the market growth.

The emerging markets including China, India, Brazil, and Mexico have become attractive destinations for companies engaged in the development, manufacturing, and distribution of cardiac ablation products. A number of factors such as success of microwave ablation procedure in clinical trials to treat atrial fibrillation, growing adoption of ablation in CVS disease treatment, and growing market penetration of ablation product manufacturers across developing countries are offering high growth opportunities for the players’ active in the Cardiac ablation market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=151399427

Advanced Cardiac Therapeutics (U.S.), Alcon Laboratories Inc. (U.S.), AngioDynamics, Inc. (U.S.), AtriCure, Inc. (U.S.), Biosense Webster Inc. (U.S.), Boston Scientific Corporation (U.S.), CONMED Corporation (U.S.), Medtronic Plc (U.S.), Olympus Corporation (Japan), and St Jude Medical, Inc. (U.S.) are some of the key players in this market.